Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation

S. Völler, RB. Flint, LM. Stolk, PLJ. Degraeuwe, SHP. Simons, P. Pokorna, DM. Burger, R. de Groot, D. Tibboel, CAJ. Knibbe, . ,

. 2017 ; 109S (-) : S90-S97. [pub] 20170512

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033897

BACKGROUND: Particularly in the pediatric clinical pharmacology field, data-sharing offers the possibility of making the most of all available data. In this study, we utilize previously collected therapeutic drug monitoring (TDM) data of term and preterm newborns to develop a population pharmacokinetic model for phenobarbital. We externally validate the model using prospective phenobarbital data from an ongoing pharmacokinetic study in preterm neonates. METHODS: TDM data from 53 neonates (gestational age (GA): 37 (24-42) weeks, bodyweight: 2.7 (0.45-4.5) kg; postnatal age (PNA): 4.5 (0-22) days) contained information on dosage histories, concentration and covariate data (including birth weight, actual weight, post-natal age (PNA), postmenstrual age, GA, sex, liver and kidney function, APGAR-score). Model development was carried out using NONMEM® 7.3. After assessment of model fit, the model was validated using data of 17 neonates included in the DINO (Drug dosage Improvement in NeOnates)-study. RESULTS: Modelling of 229 plasma concentrations, ranging from 3.2 to 75.2mg/L, resulted in a one compartment model for phenobarbital. Clearance (CL) and volume (Vd) for a child with a birthweight of 2.6kg at PNA day 4.5 was 0.0091L/h (9%) and 2.38L (5%), respectively. Birthweight and PNA were the best predictors for CL maturation, increasing CL by 36.7% per kg birthweight and 5.3% per postnatal day of living, respectively. The best predictor for the increase in Vd was actual bodyweight (0.31L/kg). External validation showed that the model can adequately predict the pharmacokinetics in a prospective study. CONCLUSION: Data-sharing can help to successfully develop and validate population pharmacokinetic models in neonates. From the results it seems that both PNA and bodyweight are required to guide dosing of phenobarbital in term and preterm neonates.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033897
003      
CZ-PrNML
005      
20181008122152.0
007      
ta
008      
181008s2017 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejps.2017.05.026 $2 doi
035    __
$a (PubMed)28506869
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Völler, Swantje $u Division of Pharmacology, Leiden Academic Center for Drug Research, Gorlaeus Laboratories, Einsteinweg 55, 2333 CC Leiden, The Netherlands. Electronic address: s.voller@lacdr.leidenuniv.nl.
245    10
$a Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation / $c S. Völler, RB. Flint, LM. Stolk, PLJ. Degraeuwe, SHP. Simons, P. Pokorna, DM. Burger, R. de Groot, D. Tibboel, CAJ. Knibbe, . ,
520    9_
$a BACKGROUND: Particularly in the pediatric clinical pharmacology field, data-sharing offers the possibility of making the most of all available data. In this study, we utilize previously collected therapeutic drug monitoring (TDM) data of term and preterm newborns to develop a population pharmacokinetic model for phenobarbital. We externally validate the model using prospective phenobarbital data from an ongoing pharmacokinetic study in preterm neonates. METHODS: TDM data from 53 neonates (gestational age (GA): 37 (24-42) weeks, bodyweight: 2.7 (0.45-4.5) kg; postnatal age (PNA): 4.5 (0-22) days) contained information on dosage histories, concentration and covariate data (including birth weight, actual weight, post-natal age (PNA), postmenstrual age, GA, sex, liver and kidney function, APGAR-score). Model development was carried out using NONMEM® 7.3. After assessment of model fit, the model was validated using data of 17 neonates included in the DINO (Drug dosage Improvement in NeOnates)-study. RESULTS: Modelling of 229 plasma concentrations, ranging from 3.2 to 75.2mg/L, resulted in a one compartment model for phenobarbital. Clearance (CL) and volume (Vd) for a child with a birthweight of 2.6kg at PNA day 4.5 was 0.0091L/h (9%) and 2.38L (5%), respectively. Birthweight and PNA were the best predictors for CL maturation, increasing CL by 36.7% per kg birthweight and 5.3% per postnatal day of living, respectively. The best predictor for the increase in Vd was actual bodyweight (0.31L/kg). External validation showed that the model can adequately predict the pharmacokinetics in a prospective study. CONCLUSION: Data-sharing can help to successfully develop and validate population pharmacokinetic models in neonates. From the results it seems that both PNA and bodyweight are required to guide dosing of phenobarbital in term and preterm neonates.
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a novorozenec nedonošený $7 D007234
650    _2
$a šíření informací $x metody $7 D033181
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a fenobarbital $x aplikace a dávkování $7 D010634
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
700    1_
$a Flint, Robert B $u Department of Pediatrics, Division of Neonatology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands.
700    1_
$a Stolk, Leo M $u Department of Clinical Pharmacy, Maastricht UMC, The Netherlands.
700    1_
$a Degraeuwe, Pieter L J $u Department of Pediatrics, Division of Neonatology, Maastricht UMC, Maastricht, The Netherlands.
700    1_
$a Simons, Sinno H P $u Department of Pediatrics, Division of Neonatology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
700    1_
$a Pokorna, Paula $u Department of Pediatrics - PICU/NICU, General University Hospital, 1st Faculty of Medicine Charles University, Prague, Czech Republic; Department of Pharmacology, General University Hospital, 1st Faculty of Medicine Charles University, Prague, Czech Republic; Intensive Care, Department of Pediatric Surgery, Department of Pediatrics, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
700    1_
$a Burger, David M $u Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
700    1_
$a de Groot, Ronald $u Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
700    1_
$a Tibboel, Dick $u Intensive Care, Department of Pediatric Surgery, Department of Pediatrics, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
700    1_
$a Knibbe, Catherijne A J $u Division of Pharmacology, Leiden Academic Center for Drug Research, Gorlaeus Laboratories, Einsteinweg 55, 2333 CC Leiden, The Netherlands; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands.
700    1_
$a ,
773    0_
$w MED00001639 $t European journal of pharmaceutical sciences official journal of the European Federation for Pharmaceutical Sciences $x 1879-0720 $g Roč. 109S, č. - (2017), s. S90-S97
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28506869 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181008122639 $b ABA008
999    __
$a ok $b bmc $g 1339645 $s 1030891
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 109S $c - $d S90-S97 $e 20170512 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur. j. pharm. sci. (Print) $x MED00001639
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace